Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 7Gastrointestinal 5Genitourinary 4CNS 4Tumor-Agnostic 3Sarcoma 1Other solid neoplasm 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Indocyanine Green × Tumor-Agnostic × Clear all
NCT02280954 2018-03-20

818012

University of Pennsylvania

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

NCT02621268 2018-03-20

ICG

University of Pennsylvania

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

NCT01884584 2017-03-09

Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer

Emory University

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡